J&J pays $2.2B upfront for Ollin to challenge Roche’s Vabysmo with phase 3 bispecific

JNJ
J&J has secured $750 million from Blackstone to fully fund the phase 3 program. (Ying Tang/NurPhoto/Getty Images)

Johnson & Johnson has struck a deal to buy Ollin Biosciences for $2.2 billion upfront, establishing itself as a threat to Roche’s blockbuster eye disease drug Vabysmo.

Ollin’s lead drug candidate, OLN324, is a bispecific antibody that hits the same targets as Vabysmo. A phase 1b trial that pitted the VEGFxAng-2 bispecifics against each other generated evidence that OLN324 drives faster and larger improvements than Roche’s incumbent. Buoyed by the data, the biotech raised $330 million in June and filed to run four phase 3 trials last month. 

Enter J&J. The drugmaker will buy Ollin for the upfront fee, plus up to $1.125 billion in regulatory and commercial milestones. J&J touted the potential for OLN324 to benefit from its scientific, development and commercial capabilities. 

The drugmaker has tapped Blackstone Life Sciences to fund OLN324 development. Blackstone will pay $750 million over multiple years to fully fund the phase 3 program. In return, J&J will pay Blackstone regulatory and sales milestones, as well as single-digit royalties. The arrangement will allow J&J to move OLN324 through late-phase development without adding to its R&D budget. 

The J&J buyout is Ollin’s reward for running a bold R&D program. After bagging rights to OLN324 from China’s Innovent Biologics, Ollin ran a head-to-head trial comparing the drug candidate to Vabysmo in neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). 

Ollin vaulted from phase 1b into its pivotal program. The biotech has filed to run two phase 3 studies in nAMD, choosing Roche’s Lucentis and Regeneron’s Eylea as the control treatments. Ollin has also filed to run two late-stage trials in DME, both of which use Eylea as the control. All the phase 3 studies have primary completion dates in December 2028, according to the federal trials database.

Successful studies could unlock major markets for J&J. Roche reported (PDF) Vabysmo sales of 3.2 billion Swiss francs ($3.8 billion) in the first nine months of 2026. Vabysmo competes with Lucentis and Eylea, including Regeneron’s high-dose version, in nAMD and DME. 

Ollin officially launched last year after being incubated by ARCH Venture Partners. The biotech's co-founder and CEO Jason Ehrlich, M.D., Ph.D., said the company has spent three years “on a mission to develop new therapies that improve the outcomes of patients with vision-threatening diseases.”

“We’ve built a relentlessly execution-focused team and have rapidly advanced OLN324, generating compelling proof-of-concept data showing the potential for more effective improvements in retinal anatomy,” Ehrlich added in a statement.